News & Updates

Show Multimedia Only

Health supplements: Help or hype?

22 Apr 2026 by

A review of 19 meta-analyses shows mixed results on the effects of multivitamin and mineral (MVM) supplementation on health outcomes.

Health supplements: Help or hype?

22 Apr 2026

Rilzabrutinib shows potential in patients with uncontrolled asthma

22 Apr 2026

BTK inhibition with rilzabrutinib does not appear to significantly decrease the incidence of loss-of-asthma-control (LOAC) event compared with placebo in patients with moderate-to-severe asthma with uncontrolled symptoms, according to a phase II study. However, the investigational drug has been associated with meaningful symptom improvements over time, despite withdrawal of background therapy.

Rilzabrutinib shows potential in patients with uncontrolled asthma

22 Apr 2026

T allele presence eases effect of air pollution on RA-ILD risk

21 Apr 2026

People exposed to air pollution for too long are at greater risk of developing rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), with the effect potentially modified according to MUC5B rs35705950 genotype, reveals a study.

T allele presence eases effect of air pollution on RA-ILD risk

21 Apr 2026

COVID-19 ups new-onset respiratory T2ID risk

20 Apr 2026 by

A study shows an association between COVID-19 infection and an elevated risk of new-onset respiratory type 2 inflammatory diseases (T2IDs), while vaccination remains protective against such diseases.

COVID-19 ups new-onset respiratory T2ID risk

20 Apr 2026

Fluvoxamine improves fatigue, QoL in long COVID patients

19 Apr 2026 by

Patients with long COVID may derive benefits from treatment with fluvoxamine, which has been shown to reduce fatigue and improve quality of life (QoL) in a study. The use of metformin, on the other hand, shows no significant advantage.

Fluvoxamine improves fatigue, QoL in long COVID patients

19 Apr 2026

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026 by

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026 by

Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026

GERD worsens cough in fibrotic interstitial lung disease

15 Apr 2026

In patients with fibrotic interstitial lung disease (ILD), the severity of cough appears to be worse in the presence of gastroesophageal reflux disease (GERD), according to a retrospective study.

GERD worsens cough in fibrotic interstitial lung disease

15 Apr 2026

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

14 Apr 2026

Oxygen therapy delivered through a high-flow nasal cannula does not appear to significantly lower mortality compared with standard oxygen therapy in patients with hypoxemic respiratory failure, according to an open-label trial.

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

14 Apr 2026

News & Updates

Showing Respirology articles

Showing

Specialty:

Health supplements: Help or hype?

Health supplements: Help or hype?

Rilzabrutinib shows potential in patients with uncontrolled asthma

Rilzabrutinib shows potential in patients with uncontrolled asthma

T allele presence eases effect of air pollution on RA-ILD risk

T allele presence eases effect of air pollution on RA-ILD risk

COVID-19 ups new-onset respiratory T2ID risk

COVID-19 ups new-onset respiratory T2ID risk

Fluvoxamine improves fatigue, QoL in long COVID patients

Fluvoxamine improves fatigue, QoL in long COVID patients

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Gotistobart a chemo-free option for metastatic sqNSCLC

Gotistobart a chemo-free option for metastatic sqNSCLC

GERD worsens cough in fibrotic interstitial lung disease

GERD worsens cough in fibrotic interstitial lung disease

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure

High-flow oxygen therapy provides no survival advantage in hypoxemic respiratory failure